Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 253-258

  Margulis, Vitaly ^b   Wood, Christopher G ^b   Jonasch, Eric ^b   Matin, Surena F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LYMPHADENOPATHY; MONOTHERAPY; NEPHRECTOMY; PARAAORTIC LYMPH NODE; PREOPERATIVE TREATMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL TECHNIQUE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR VASCULARIZATION; KIDNEY TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY; PROTEIN KINASE INHIBITORS;

EID: 58149132465     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0038-3     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Motzer RJ, Bacik J, Schwartz LH, et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463.
3. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028-1043.
4. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
5. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
7. Montie JE, Stewart BH, Straffon RA, et al.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977, 117:272-275.
8. Dekernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 1978, 120:148-152.
9. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
10. Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 2001, 358:966-970.
11. Flanigan RC, Mickisch G, Sylvester R, et al.: Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 2004, 171:1071-1076.
12. Marcus SG, Choyke PL, Reiter R, et al.: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993, 150:463-466.
13. Vieweg J, Su Z, Dahm P, Kusmartsev S: Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007, 13:727s-732s.
14. Kudoh S, Redovan C, Rayman P, et al.: Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother (1997) 1997, 20:479-487.
15. Schleypen JS, Baur N, Kammerer R, et al.: Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006, 12:718-725.
16. Tatsumi T, Kierstead LS, Ranieri E, et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
17. Tatsumi T, Herrem CJ, Olson WC, et al.: Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481-4489.
18. Uzzo RG, Rayman P, Kolenko V, et al.: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells. J Clin Invest 1999, 104:769-776.
19. Gatenby RA, Gawlinski ET, Tangen CM, et al.: The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002, 62:5218-5222.
20. Dosquet C, Coudert MC, Lepage E, et al.: Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997, 3:2451-2458.
21. Edgren M, Lennernäs B, Larsson A, Nilsson S: Serum concentrations of VEGF and β-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 1999, 19:869-873.
22. Jacobsen J, Grankvist K, Rasmuson T, et al.: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004, 93:297-302.
23. Feldman AL, Alexander HR Jr, Yang JC, et al.: Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002, 95:1637-1643.
24. Clayman RV: Laparoscopic radOcal nephrectomy: oncologic efficacy. J Urol 2005, 173:1201.
25. Permpongkosol S, Chan DY, Link RE, et al.: Laparoscopic radical nephrectomy: Long-term outcomes. J Endourol 2005, 19:628-633.
26. Walther MM, Lyne JC, Libutti SK, Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology 1999, 53:496-501.
27. Rabets JC, Kaouk J, Fergany A, et al.: Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004, 64:930-934.
28. Matin SF, Madsen LT, Wood CG: Laparoscopic cytoreductive nephrectomy: the M.D. Anderson Cancer Center experience. Urology 2006, 68:528-532.
29. Jonasch E: Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2007, 7:73-78.
30. Wood CG: Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: Combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007, 13:697s-702s.
31. Motzer RJ, Bacik J, Mariani T, et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002, 20:2376-2381.
32. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al.: Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007, 178:1896-1900.
33. Fallick ML, McDermott DF, LaRock D, et al.: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691-1695.
34. Han KR, Pantuck AJ, Bui MH, et al.: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003, 61:314-319.
35. Wood CG: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003, 30:581-588.
36. Pantuck AJ, Zisman A, Dorey F, et al.: Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995-3002.
37. Vasselli JR, Yang JC, Linehan WM, et al.: Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166:68-72.
38. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
39. Leibovich BC, Cheville JC, Lohse CM, et al.: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol 2005, 174:1759-1763; discussion 1763.
40. Motzer RJ, Figlin RA, Hutson TE, et al.: Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):5024.